Efficacy and tolerability of sitagliptin and metformin compared with insulin as an initial therapy for newly diagnosed diabetic patients with severe hyperglycaemia

Mingqian He, Mei Deng, Jingya Wang, Pengxia Fan, Yue Wang, Xinrui Zhao, Yizhi He, Bingyin Shi, Jing Sui, Mingqian He, Mei Deng, Jingya Wang, Pengxia Fan, Yue Wang, Xinrui Zhao, Yizhi He, Bingyin Shi, Jing Sui

Abstract

The safety and efficacy of dipeptidyl peptidase-4 inhibitors in patients newly diagnosed type 2 diabetes mellitus (T2DM) with severe hyperglycaemia have remained to be sufficiently demonstrated. The aim of the present study was to determine whether sitagliptin combined with metformin as an initial treatment had non-inferior outcomes with regards to glycaemic remission and β-cell function recovery to those of standard insulin therapy in this patient group. A prospective observational study was performed comparing the effects of sitagliptin combined with metformin and insulin therapy in a real-world clinical setting. A total of 168 participants were enrolled and received sitagliptin combined with metformin (Sig) or insulin (Ins) for almost 4 weeks. In addition, each group was further stratified into three subgroups, according to glycosylated haemoglobin (HbA1c) levels (<10, 10-12 and >12%). The primary outcomes were β-cell function and changes in fasting plasma glucose (FPG) and HbA1c at the 3-month follow-up. Both insulin and sitagliptin combined with metformin reduced hyperglycaemia and achieved similar glycaemic outcomes, and no significant differences in FPG and HbA1c levels were obtained. No significant changes were observed in β-cell function concomitant with the glucose-lowering effects of the treatments. Of note, participants in the Ins group exhibited weight gain, whereas those in the Sig group had weight loss, with significant differences becoming evident after 1 month, particularly in the HbA1c <10% subgroup. As compared with insulin injection, early treatment with sitagliptin combined with metformin in newly diagnosed patients with T2DM and severe hyperglycaemia produced non-inferior outcomes with regards to glycaemic remission. Therefore, combination of sitagliptin and metformin may be a viable initial treatment option for patients who prefer an alternative to insulin injection. This study was registered with ClinicalTrials.gov under no. NCT03180281.

Keywords: dipeptidyl peptidase-4 inhibitor; initial insulin therapy; severe hyperglycaemia; sitagliptin; type 2 diabetes mellitus.

Copyright: © He et al.

Figures

Figure 1
Figure 1
Comparison of average time to achieve euglycaemia in subgroups stratified by baseline HbA1c. ***P<0.001. Treatment groups: Sig, sitagliptin combined with metformin; Ins, insulin. HbA1c, glycosylated haemoglobin.

References

    1. Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia. 2001;44(929) doi: 10.1007/s001250100580.
    1. 15. Diabetes care in the hospital: Standards of medical care in diabetes-2020. Diabetes Care. 2020;43 (Suppl 1):S193–S202. doi: 10.2337/dc20-S015. American Diabetes Association.
    1. Haak T. Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia. Adv Ther. 2012;29:1005–1015. doi: 10.1007/s12325-012-0066-0.
    1. 5. Lifestyle management: Standards of medical care in diabetes-2019. Diabetes Care. 2019;42 (Suppl 1):S46–S60. doi: 10.2337/dc19-S005. American Diabetes Association.
    1. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm-2017 executive summary. Endocr Pract. 2017;23:207–238. doi: 10.4158/EP161682.CS.
    1. Diabetes Care. 2016;39 (Suppl 1):S52–S59. American Diabetes Association Approaches to glycemic treatment. Sec. 7. In standards of medical care in diabetes-2016.
    1. 9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2019. Diabetes Care. 2019;42 (Suppl 1):S90–S102. doi: 10.2337/dc19-S009. American Diabetes Association.
    1. Pastores SM. ACP journal club. Review: Intensive insulin therapy does not reduce mortality but increases severe hypoglycemia in hospitalized patients. Ann Intern Med. 2011;155:JC1–JC12. doi: 10.7326/0003-4819-155-2-201107190-02012.
    1. Nyenwe E. Intensive insulin therapy in hospitalised patients increases the risk of hypoglycaemia and has no effect on mortality, infection risk or length of stay. Evid Based Med. 2012;17:8–9. doi: 10.1136/ebm1413.
    1. Aleali AM, Payami SP, Latifi SM, Yazdanpanah L, Hesam S, Khajeddin N. Evaluation of psychological resistance to insulin treatment in type II diabetic patients. Diabetes Metab Syndr. 2018;12:929–932. doi: 10.1016/j.dsx.2018.05.017.
    1. Sanchez-Rangel E, Inzucchi SE. Metformin: Clinical use in type 2 diabetes. Diabetologia. 2017;60:1586–1593. doi: 10.1007/s00125-017-4336-x.
    1. Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: The PIONEER 8 trial. Diabetes Care. 2019;42:2262–2271. doi: 10.2337/dc19-0898. PIONEER 8 Investigators.
    1. Scott R, Morgan J, Zimmer Z, Lam RLH, O'Neill EA, Kaufman KD, Engel SS, Raji A. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. Diabetes Obes Metab. 2018;20:2876–2884. doi: 10.1111/dom.13473.
    1. Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4) Best Pract Res Clin Endocrinol Metab. 2009;23:479–486. doi: 10.1016/j.beem.2009.03.004.
    1. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004;89:2078–2084. doi: 10.1210/jc.2003-031907.
    1. Dicker D. DPP-4 inhibitors: Impact on glycemic control and cardiovascular risk factors. Diabetes Care. 2011;34 (Suppl 2):S276–S278. doi: 10.2337/dc11-s229.
    1. Standards of medical care in diabetes-2013. Diabetes Care. 2013;36 (Suppl 1):S11–S66. doi: 10.2337/dc13-S011. American Diabetes Association.
    1. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419. doi: 10.1007/BF00280883.
    1. Burden RL, Faires JD. Numerical analysis. J R Statist Soc. 2005;71:48–50.
    1. Li Q, Wang L, Xiao L, Wang Z, Wang F, Yu X, Yan S, Wang Y. Effect of intensive insulin therapy on first-phase insulin secretion in newly diagnosed type 2 diabetic patients with a family history of the disease. Exp Ther Med. 2015;9:612–618. doi: 10.3892/etm.2014.2114.
    1. Li G, Yang W, Jiang Y. The possibility of (FINSxFPG)/(PG2h+PG1h-2FPG) being taken as an index of pancreatic β cell insulin secretion in a population based study. Chin J Intern Med. 2000;13:191–196.
    1. Kang X, Wang C, Chen D, Lv L, Liu G, Xiao J, Yang Y, He L, Chen L, Li X, et al. Contributions of basal glucose and postprandial glucose concentrations to hemoglobin A1c in the newly diagnosed patients with type 2 diabetes-the preliminary study. Diabetes Technol Ther. 2015;17:445–448. doi: 10.1089/dia.2014.0327.
    1. Weir GC, Marselli L, Marchetti P, Katsuta H, Jung MH, Bonner-Weir S. Towards better understanding of the contributions of overwork and glucotoxicity to the beta-cell inadequacy of type 2 diabetes. Diabetes Obes Metab. 2009;11 (Suppl 4):82–90. doi: 10.1111/j.1463-1326.2009.01113.x.
    1. Defronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36 (Suppl 2):S127–S138. doi: 10.2337/dcS13-2011.
    1. Lyu X, Zhu X, Zhao B, Du L, Chen D, Wang C, Liu G, Ran X. Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: Meta-analysis of randomized controlled trials. Sci Rep. 2017;7(44865) doi: 10.1038/srep44865.
    1. Cnop M, Vidal J, Hull RL, Utzschneider KM, Carr DB, Schraw T, Scherer PE, Boyko EJ, Fujimoto WY, Kahn SE. Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care. 2007;30:677–382. doi: 10.2337/dc06-1834.
    1. Mu J, Petrov A, Eiermann GJ, Woods J, Zhou YP, Li Z, Zycband E, Feng Y, Zhu L, Roy RS, et al. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol. 2009;623:148–154. doi: 10.1016/j.ejphar.2009.09.027.
    1. Heise T, Larbig M, Patel S, Seck T, Hehnke U, Woerle HJ, Dugi K. The dipeptidyl peptidase-4 inhibitor linagliptin lowers postprandial glucose and improves measures of β-cell function in type 2 diabetes. Diabetes Obes Metab. 2014;16:1036–1039. doi: 10.1111/dom.12312.
    1. Leibowitz G, Cahn A, Bhatt DL, Hirshberg B, Mosenzon O, Wei C, Jermendy G, Sheu WH, Sendon JL, Im K, et al. Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study. Diabetes Obes Metab. 2015;17:487–494. doi: 10.1111/dom.12445.
    1. Tarantino G, Citro V, Capone D. Nonalcoholic fatty liver disease: A challenge from mechanisms to therapy. J Clin Med. 2019;9(15) doi: 10.3390/jcm9010015.
    1. Iwasaki T, Yoneda M, Inamori M, Shirakawa J, Higurashi T, Maeda S, Terauchi Y, Nakajima A. Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology. 2011;58:2103–2105. doi: 10.5754/hge11263.
    1. Zhou FL, Ye F, Berhanu P, Gupta VE, Gupta RA, Sung J, Westerbacka J, Bailey TS, Blonde L. Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 U/ml vs other basal insulins in patients with type 2 diabetes using basal insulin. Diabetes Obes Metab. 2018;20:1293–1297. doi: 10.1111/dom.13199.
    1. Kelany ME, Hakami TM, Omar AH, Abdallah MA. Combination of sitagliptin and insulin against type 2 diabetes mellitus with neuropathy in rats: Neuroprotection and role of oxidative and inflammation stress. Pharmacology. 2016;98:242–250. doi: 10.1159/000448043.
    1. Ramírez E, Picatoste B, González-Bris A, Oteo M, Cruz F, Caro-Vadillo A, Egido J, Tuñón J, Morcillo MA, Lorenzo Ó. Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: Role of GLP-1 isoforms in Glut4 receptor trafficking. Cardiovasc Diabetol. 2018;17(12) doi: 10.1186/s12933-017-0643-2.
    1. 4. Lifestyle management: Standards of medical care in diabetes-2018. Diabetes Care. 2018;41 (Suppl 1):S38–S50. doi: 10.2337/dc18-S004. American Diabetes Association.
    1. Bertakis KD, Azari R, Helms LJ, Callahan EJ, Robbins JA. Gender differences in the utilization of health care services. J Fam Pract. 2000;49:147–452.
    1. Babu A, Mehta A, Guerrero P, Chen Z, Meyer PM, Koh CK, Roberts R, Schaider J, Fogelfeld L. Safe and simple emergency department discharge therapy for patients with type 2 diabetes mellitus and severe hyperglycemia. Endocr Pract. 2009;15:696–704. doi: 10.4158/EP09117.ORR.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi